The xanthine oxidase (XO) plays an important role in producing uric acid, and therefore XO inhibitors are considered as one of the promising therapies for hyperuricemia and gout. We have previously reported a series of XO inhibitors with pyrazole scaffold to extend the chemical space of current XO inhibitors. Herein, we describe further structural optimization to explore the optimal heterocycle by replacing the thiazole ring of Febuxostat with 5 heterocycle scaffolds unexplored in this field. All of these efforts resulted in the identification of compound 8, a potent XO inhibitor (IC50 = 48.6 nM) with novel 2-phenylthiazole-4-carboxylic acid scaffold. Moreover, lead compound 8 exhibited hypouricemic effect in potassium oxonate-hypoxanthine-induced hyperuricemic mice. These results promote the understanding of ligand-receptor interaction and might help to design more promising XO inhibitors.

中文翻译：

---

发现了2-苯基噻唑-4-羧酸，一种新型有效的黄嘌呤氧化酶抑制剂。

黄嘌呤氧化酶（XO）在产生尿酸中起着重要作用，因此XO抑制剂被认为是高尿酸血症和痛风的有前途的疗法之一。我们先前已经报道了一系列带有吡唑骨架的XO抑制剂，以扩展当前XO抑制剂的化学空间。在这里，我们描述了进一步的结构优化，以通过用该领域未开发的5个杂环骨架取代非布索坦的噻唑环来探索最佳杂环。所有这些努力导致了化合物8的鉴定，该化合物是一种具有新型2-苯基噻唑-4-羧酸支架的有效XO抑制剂（IC50 = 48.6 nM）。此外，铅化合物8在草酸钾-次黄嘌呤诱导的高尿酸血症小鼠中表现出低尿酸作用。